A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult Subjects
Abroad (travel likely)RecruitingPHASE1
Conditions
Healthy
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
ICON Early Clinical & Bioanalytical Solutions, Groningen, Netherlands
Study leads
Thomas Kaindl, MD
Study Director
Basilea Pharmaceutica International Ltd, Allschwil